# A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

> **NCT06471673** · PHASE1,PHASE2 · RECRUITING · sponsor: **BriaCell Therapeutics Corporation** · enrollment: 18 (estimated)

## Conditions studied

- Breast Cancer
- Breast Tumor
- Cancer of Breast
- Cancer of the Breast
- Malignant Tumor of Breast
- Tumors, Breast

## Interventions

- **BIOLOGICAL:** BC1 cell line
- **BIOLOGICAL:** Bria-OTS regimen and CPI (tislelizumab)
- **BIOLOGICAL:** Bria-OTS regimen and CPI (tislelizumab) expansion cohort

## Key facts

- **NCT ID:** NCT06471673
- **Lead sponsor:** BriaCell Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06471673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06471673, "A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT06471673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*